» Articles » PMID: 15815004

Epidemiology and Predictors of Mortality in Cases of Candida Bloodstream Infection: Results from Population-based Surveillance, Barcelona, Spain, from 2002 to 2003

Abstract

We conducted population-based surveillance for Candida bloodstream infections in Spain to determine its incidence, the extent of antifungal resistance, and risk factors for mortality. A case was defined as the first positive blood culture for any Candida spp. in a resident of Barcelona, from 1 January 2002 to 31 December 2003. We defined early mortality as occurring between days 3 to 7 after candidemia and late mortality as occurring between days 8 to 30. We detected 345 cases of candidemia, for an average annual incidence of 4.3 cases/100,000 population, 0.53 cases/1,000 hospital discharges, and 0.73 cases/10,000 patient-days. Outpatients comprised 11% of the cases, and 89% had a central venous catheter (CVC) at diagnosis. Overall mortality was 44%. Candida albicans was the most frequent species (51% of cases), followed by Candida parapsilosis (23%), Candida tropicalis (10%), Candida glabrata (8%), Candida krusei (4%), and other species (3%). Twenty-four isolates (7%) had decreased susceptibility to fluconazole (MIC > or = 16 microg/ml). On multivariable analysis, early death was independently associated with hematological malignancy (odds ratio [OR], 3.5; 95% confidence interval [CI], 1.1 to 10.4). Treatment with antifungals (OR, 0.05; 95% CI, 0.01 to 0.2) and removal of CVCs (OR, 0.3; 95% CI, 0.1 to 0.9) were protective factors for early death. Receiving adequate treatment, defined as having CVCs removed and administration of an antifungal medication (OR, 0.2; 95% CI, 0.08 to 0.8), was associated with lower odds of late mortality; intubation (OR, 7.5; 95% CI, 2.6 to 21.1) was associated with higher odds. The incidence of candidemia and prevalence of fluconazole resistance are similar to other European countries, indicating that routine antifungal susceptibility testing is not warranted. Antifungal medication and catheter removal are critical in preventing mortality.

Citing Articles

An 11-Year retrospective analysis of candidiasis epidemiology, risk factors, and antifungal susceptibility in a tertiary care hospital in China.

Khan S, Cai L, Bilal H, Khan M, Fang W, Zhang D Sci Rep. 2025; 15(1):7240.

PMID: 40021727 PMC: 11871059. DOI: 10.1038/s41598-025-92100-x.


Biological activities of lichen extracts and UHPLC-ESI-QTOF-MS analysis of their secondary metabolites.

Pineiro M, Manrique S, Gomez J, Rodriguez J, Barrera P, Caballero D Front Pharmacol. 2025; 15():1508835.

PMID: 39834815 PMC: 11742939. DOI: 10.3389/fphar.2024.1508835.


Molecular characterization of non- yeast communities isolated from trees.

Nouraei H, Gharechahi F, Zareshahrabadi Z, Zomorodian K, Gharavi A, Khodadadi H Curr Med Mycol. 2025; 10.

PMID: 39744339 PMC: 11686939. DOI: 10.22034/CMM.2024.345184.1500.


Biofilm formation and increased mortality among cancer patients with candidemia in a Peruvian reference center.

Villanueva-Cotrina F, Bejar V, Guevara J, Cajamarca I, Medina C, Mujica L BMC Infect Dis. 2024; 24(1):1145.

PMID: 39395965 PMC: 11470705. DOI: 10.1186/s12879-024-10044-5.


Candidaemia: A 9-Year Retrospective Analysis of Epidemiology and Antimicrobial Susceptibility in Tertiary Care Hospitals in Western China.

Li K, Yang X, Li L, Zhi L Infect Drug Resist. 2024; 17:3891-3900.

PMID: 39253608 PMC: 11382801. DOI: 10.2147/IDR.S477815.


References
1.
Viudes A, Peman J, Canton E, Ubeda P, Lopez-Ribot J, Gobernado M . Candidemia at a tertiary-care hospital: epidemiology, treatment, clinical outcome and risk factors for death. Eur J Clin Microbiol Infect Dis. 2002; 21(11):767-74. DOI: 10.1007/s10096-002-0822-1. View

2.
Viscoli C, Girmenia C, Marinus A, Collette L, Martino P, Vandercam B . Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis. 1999; 28(5):1071-9. DOI: 10.1086/514731. View

3.
Kossoff E, Buescher E, Karlowicz M . Candidemia in a neonatal intensive care unit: trends during fifteen years and clinical features of 111 cases. Pediatr Infect Dis J. 1998; 17(6):504-8. DOI: 10.1097/00006454-199806000-00014. View

4.
Motzer R, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J . Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999; 17(8):2530-40. DOI: 10.1200/JCO.1999.17.8.2530. View

5.
Wingard J . Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis. 1995; 20(1):115-25. DOI: 10.1093/clinids/20.1.115. View